Loading...

Innovative Drug Synthesis

Share Icon

ISBN: 978-1-118-82005-6

December 2015

360 pages

Description

Discover the cutting-edge science driving the medicinal chemistry and synthesis of the latest drugs

Continuing the tradition of the acclaimed prior volumes on drug synthesis, Innovative Drug Synthesis illustrates how chemistry, biology, pharmacokinetics, and related disciplines come together to produce successful medicines. This book covers all aspects of the medicinal chemistry of the latest drugs and the cutting-edge science associated with them. With authoritative coverage by distinguished editors and authors analyzing the pros and cons of different synthetic routes, the book demystifies the process of modern drug discovery for practitioners and researchers.

Other highlights include:

  • Summary of respective disease area, important properties and SAR (structure–activity relationship), and chemical synthesis routes/options for each covered drug
  • A step-by-step breakdown of today's drug discovery process for professionals and students
  • Chapters on drugs that have achieved breakthrough therapy designation such as sofosbuvir, palbociclib, and more

Innovative Drug Synthesis shows that whether drug synthesis is in early development or the process stage, the ability to design elegant and economical synthetic routes is often a major factor making a drug a commercial winner. Easy to follow and stacked with valuable information on the present and future direction of medicinal chemistry, Innovative Drug Synthesis paints a clear and complete picture of this complex subject.

About the Author

Jie Jack Li is an Associate Professor of chemistry at the University of San Francisco. Previously, he was a Discovery Chemist at Bristol-Myers Squibb and Pfizer. He has authored or edited over 20 books and several of those were published by Wiley, including Drug Discovery: Practices, Processes, and Perspectives, Heterocyclic Chemistry in Drug Discovery, Name Reactions in Heterocyclic Chemistry, Name Reactions for Functional Group Transformations, Contemporary Drug Synthesis, The Art of Drug Synthesis, and Modern Drug Synthesis

Douglas S. Johnson is a Research Fellow and Head of Chemical Biology in the Neuroscience Medicinal Chemistry group at Pfizer Worldwide Research and Development. He is a co-author on more than 75 publications and patents and is a co-author of the book Contemporary Drug Synthesis and is an editor of The Art of Drug Synthesis, and Modern Drug Synthesis (all published by Wiley).